Cerebral Therapeutics™ Inc. is a privately-held company founded with the goal of addressing medically refractory epilepsy.
Led by experts in the fields of Brain Drug and Device Development, Cerebral Therapeutics™ addresses chronic neurological diseases using novel and proprietary drugs administered directly to the brain.
By bypassing the blood-brain barrier, Cerebral’s therapies are designed to maximize medication efficacy while greatly reducing systemic exposure and enhancing drug regimen compliance.
To provide a unique approach to improve the lives of patients suffering from chronic neurological diseases, particularly those for whom oral and I.V. infused medicines are either not effective, and/or are limited by systemic medication side effects. The company’s development activities are focusing towards providing an alternative treatment to those patients who continue to have seizures despite taking conventional orally administered medications.